Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | BCHE | P06276 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.36 |
| ▸ | ANPEP | P15144 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.32 |
| ▸ | IDO1 | P14902 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8935522 | 0.78 | CYP2D6 (0.40) | CYP2D6MEN1RECQLKMT2ABCHE | |
| SCHEMBL840754 | 0.74 | NOS3 (0.47) | CYP2D6MEN1RECQLKMT2AACHE | |
| SCHEMBL6802213 | 0.73 | CYP2D6 (0.38) | CYP2D6MEN1RECQLKMT2ACTSD | |
| SCHEMBL4589465 | 0.73 | CYP2D6 (0.38) | CYP2D6MEN1RECQLKMT2AACHE | |
| SCHEMBL2449959 | 0.72 | CYP2D6 (0.39) | CYP2D6MEN1RECQLKMT2ABCHE | |
| SCHEMBL1515132 | 0.72 | CYP2D6 (0.39) | CYP2D6MEN1RECQLKMT2ABCHE | |
| SCHEMBL2449491 | 0.72 | CYP2D6 (0.39) | CYP2D6MEN1RECQLKMT2ABCHE | |
| SCHEMBL7691240 | 0.71 | ACHE (0.44) | MEN1KMT2AACHENOS3NOS2 | |
| SCHEMBL3377490 | 0.71 | MAPT (0.41) | CYP2D6MEN1RECQLKMT2ANOS3 | |
| SCHEMBL7295206 | 0.71 | MAPT (0.41) | CYP2D6MEN1RECQLKMT2ANOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0221958-B1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Louis, William John (AU) | 1992-10-28 | — | — | EP | claimed |
| US-4977153-A | BETA ADRENOCEPTOR BLOCKING AGENTS | Louis, William J. (AU) | 1990-12-11 | — | — | US | claimed |
| EP-0221958-A4 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | LOUIS WILLIAM JOHN (AU) | 1987-11-25 | — | — | EP | claimed |
| EP-0221958-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | LOUIS WILLIAM JOHN (AU) | 1987-05-20 | — | — | EP | claimed |
| WO-1986006717-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LOUIS WILLIAM JOHN (AU) | 1986-11-20 | — | — | WO | claimed |
| US-20100324091-A1 | Pyrazolone Derivative | KOWA COMPANY, LTD. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2172458-A1 | PYRAZOLONE DERIVATIVE | Kowa Company, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
| EP-0221958-B1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Louis, William John (AU) | 1992-10-28 | — | — | EP | disclosed |
| US-4977153-A | BETA ADRENOCEPTOR BLOCKING AGENTS | Louis, William J. (AU) | 1990-12-11 | — | — | US | disclosed |
| EP-0313081-A2 | 2-Oxa-isocephem compounds, compositions containing the same and processes for preparing the same | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-04-26 | — | — | EP | disclosed |
| EP-0221958-A4 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | LOUIS WILLIAM JOHN (AU) | 1987-11-25 | — | — | EP | disclosed |
| EP-0221958-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. | LOUIS WILLIAM JOHN (AU) | 1987-05-20 | — | — | EP | disclosed |
| WO-1986006717-A1 | 3-AMINOPROPYLOXYPHENYL DERIVATIVES THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | LOUIS WILLIAM JOHN (AU) | 1986-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324091-A1 | Pyrazolone Derivative | SERPINE1, SERPINC1, TFPI | CYP2D6 1265/4885MEN1 2985/4885RECQL 2623/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.